High apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative study

Basit Öğe Kaydı
dc.contributor.authorMaden, Muhammet
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorPamuk, Gulsum Emel
dc.date.accessioned2024-06-12T11:08:47Z
dc.date.available2024-06-12T11:08:47Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBACKGROUND: Apelin/APJ system regulates angiogenesis and is overexpressed in some malignancies. Apelin can induce lymphangiogenesis and lymph node metastasis. OBJECTIVE: We evaluated apelin levels in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL); and analyzed the association between apelin levels and clinical findings. METHODS: We included consecutive 29 MM, 31 NHL patients, and 19 healthy controls. Patients' demographic and clinical features, treatment modalities, and responses were recorded from hospital records. Plasma apelin was determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: MM patients had significantly higher plasma apelin level than NHL and healthy control groups (p < 0.001). Apelin level in NHL group was similar to controls (p > 0.05). ROC curve analysis showed that the area under the curve value for apelin level in MM was 0.842 ng/ml (95% CI: 0.739-0.945, p < 0.001). Plasma apelin level >= 0.827 ng/ml had 76% sensitivity and 86% specificity for the diagnosis of MM. Multivariate Cox regression analysis showed that MM patients with high apelin level had better prognosis and patients with advanced stage of disease (ISS-3) had significantly poor prognosis when compared to others. In the MM group, apelin level correlated negatively with LDH (r = -0.39, p = 0.038). CONCLUSIONS: In MM, plasma apelin level was significantly higher than in NHL and control groups. Apelin could be playing a role in MM pathogenesis; and apelin level could be used as a diagnostic and prognostic biomarker in MM.en_US
dc.identifier.doi10.3233/CBM-160654
dc.identifier.endpage396en_US
dc.identifier.issn1574-0153
dc.identifier.issn1875-8592
dc.identifier.issue4en_US
dc.identifier.pmid27689615en_US
dc.identifier.scopus2-s2.0-85009291218en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage391en_US
dc.identifier.urihttps://doi.org/10.3233/CBM-160654
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22568
dc.identifier.volume17en_US
dc.identifier.wosWOS:000393748400004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIos Pressen_US
dc.relation.ispartofCancer Biomarkersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Myelomaen_US
dc.subjectNon-Hodgkin Lymphomaen_US
dc.subjectApelinen_US
dc.subjectSurvivalen_US
dc.subjectNon-Hodgkin-Lymphomaen_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectBone-Marrowen_US
dc.subjectAngiogenic Factoren_US
dc.subjectReceptoren_US
dc.subjectCellsen_US
dc.subjectApjen_US
dc.subjectLiganden_US
dc.subjectVegfen_US
dc.subjectContractilityen_US
dc.titleHigh apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu